BACKGROUND:Optimizing plastic surgeon distribution is essential to meeting rising consumer demand for aesthetic operations. OBJECTIVES:This study aimed to identify aesthetic surgery demand-supply mismatches across U.S. Designated Market Areas (DMAs) and quantify regional demand changes from pre- to post-COVID periods. METHODS:This cross-sectional ecological analysis used Google Trends (Google LLC, Mountain View, CA, USA) Relative Search Volume (RSV) averaged for nine aesthetic operations as a proxy for demand across 210 DMAs from August 2024-2025. Surgeon concentration was calculated as board-certified plastic surgeons per 10,000 residents. Demand-Supply Ratio (DSR) was defined as RSV divided by surgeon concentration. DMAs were grouped into quintiles (Tiers 1-5, highest to lowest DSR). RESULTS:Median RSV was 45.03 (Interquartile Range [IQR] 39.52-54.90) and median surgeon density was 0.10 (IQR 0.06-0.17). Seventeen DMAs (8.1%) were "plastic surgery deserts," with search activity but no surgeons, clustering in the South, Midwest, and West. Median DSR was 426.16 (IQR 307.35-565.08), with highest DSRs concentrated in Southern and rural/interior DMAs, whereas coastal hubs were saturated. While surgeon concentration increased across DSR Tiers 1-5, RSV did not significantly differ. Nationally, median RSV increased 22.54% (IQR 16.65%-32.34%) from 2018-2019 to 2024-2025, with rising RSV in 95.2% of DMAs and highest growth in the Midwest (+32.58%, IQR 24.90%-47.55%). CONCLUSIONS:Southern and rural DMAs are disproportionately represented among underserved aesthetic markets and plastic surgery deserts. Aesthetic demand is rising nationwide, particularly in the American interior, underscoring high-growth regions where strategic expansion of aesthetic services by board-certified plastic surgeons may improve patient access and safety.
BACKGROUND:Olorofim is an antifungal agent with a novel mechanism of action against Aspergillus spp., rare moulds and dimorphic fungi. Preclinical studies reported unidirectional antagonism between olorofim and mould-active azoles (e.g. azoles other than fluconazole) against Aspergillus fumigatus in which the azole reduces the antifungal effect of olorofim. METHODS:To assess the potential clinical impact of this preclinical finding, we compared outcomes of olorofim with and without concomitant azoles from a Phase 2b salvage study in patients with invasive fungal diseases with few or no treatment options. RESULTS:Analyses are limited by the study size but outcomes were similar for olorofim with and without an azole in combination (whether mould-active or not) at Days 42 (the primary study endpoint) and 84 for both Mycoses Study Group-European Organization for Research and Treatment of Cancer (MSG-EORTC) responses and for all-cause mortality in patients with aspergillosis (77 not receiving an azole, 24 receiving an azole in combination), in patients with coccidioidomycosis (11 not receiving an azole, 30 receiving an azole in combination) and in patients with other fungal infections (50 not receiving an azole, 10 receiving an azole in combination). In addition, the rate of drug-induced liver injury was not increased in patients receiving combination with an azole. CONCLUSIONS:Although limited by small numbers of patients for individual fungi, this analysis did not demonstrate a pattern of reduced clinical efficacy or tolerability of olorofim when given in combination with either the mould-active azoles or with fluconazole.Trial registration number. NCT03583164.
To establish parameters for congenital cervical stenosis (CCS) using computed tomography (CT), assessing influences of patient sex, race, and ethnicity. Measurements were collected of anteroposterior diameter (APD), interpedicular distance (IPD) and cervical intervertebral foramen dimensions (CIFD) from 1000 patients between 18 and 35 years of age without spinal pathology. CCS was determined as two standard deviations below the mean of the collected measurements. Irrespective of vertebral level, mean anatomic APD, CIFD and IPD measurements were as follows: 14.94 ± 1.99 mm for APD, 6.58 ± 1.45 mm and 6.68 ± 1.45 mm for left and right widths, of 9.30 ± 2.30 mm and 9.25 ± 2.80 mm for left and right heights, 57.0 ± 19.2 mm2 and 59.5 ± 20.3 mm2 for left and right areas, and 25.4 ± 1.78 mm for IPD. Irrespective of vertebral level, threshold values for CCS were 10.96 mm for APD, 3.68 mm and 3.78 mm for left and right widths, of 4.70 mm and 3.65 mm for left and right heights, 20.6 mm2 and 19 mm2 for left and right areas, and 21.8 mm for IPD. Males demonstrated larger CCS threshold values than females for left and right CIFD area and APD. African American patients had smaller CIFDs and APD, and subsequent CCS thresholds compared to White patients. This study reports measurements of CIFD, IPD, and APD to establish quantitative thresholds for diagnosis of CCS. CCS thresholds were significantly influenced by patient sex, race, and ethnicity.
RATIONALE:Dyspnea is a prominent symptom of fibrotic hypersensitivity pneumonitis (fHP), limiting patients' activity and impairing their quality of life. The University of California San Diego Shortness of Breath questionnaire (UCSD-SOBQ) is a 24-item instrument used to assess dyspnea severity in patients with various respiratory conditions. OBJECTIVES:This study aimed to examine the reliability and responsiveness of the UCSD-SOBQ score, its validity as a measure of dyspnea severity, and its prognostic value in a prospective cohort with fHP. METHODS:We conducted psychometric analyses on UCSD-SOBQ response data and assessed the association between score changes and survival in patients with fHP who completed the UCSD-SOBQ and other HP severity metrics at baseline, 6 and 12 months. We introduce the reliable change index (RCI) and the likely change index (LCI) to assess the statistical significance of within-individual change in UCSD scores. RESULTS:At baseline, internal consistency was high (Cronbach's alpha = 0.97). Significant moderately strong correlations were observed between UCSD-SOBQ scores and percent predicted forced vital capacity (FVC%), r = -0.46, percent predicted diffusing capacity of the lung for carbon monoxide (DLCO%), r = -0.32, and Borg dyspnea scores r = 0.56. UCSD-SOBQ scores were significantly different between the lowest and highest strata of FVC% (64.9 ± 18.9 vs. 36.2 ± 22.9), DLCO% and Borg scores. The threshold for worsening within-individual change in the UCSD-SOBQ score at 95% confidence was 12 points. A 1-point higher baseline UCSD-SOBQ score was associated with a 2% increase in the risk of death or transplant (HR 1.02, 95% CI 1.00, 1.04). CONCLUSIONS:In fHP, the UCSD-SOBQ score is a reliable and valid measure of dyspnea severity, is responsive to change, discriminates patients with differing severities, and is associated with transplant free survival. Additional qualitative data and psychometric analyses could tailor the UCSD-SOBQ to fHP and may further improve its measurement properties.
Introduction Treatment for steroid refractory immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Anakinra, an IL-1 antagonist, has shown a treatment related mortality benefit at higher doses; however, median time to resolution is 7 days. Several series of intrathecal chemotherapy (IT) +/- steroids have shown some benefit.In 2023, our institution adopted IT therapy with methotrexate and hydrocortisone for patients with severe or persistent ICANS to decrease systemic steroid use and infection risk with high-dose steroids, and to improve response time. Objectives The primary objective of this retrospective review was to determine the time from IT therapy administration to resolution of ICANS. Secondary outcomes included time to resolution of ICANS with earlier vs later IT administration. Methods A SlicerDicer Epic report was run for all patients > 18 years old who received a commercial CAR-T therapy and subsequent IT therapy with methotrexate 12 mg and hydrocortisone 50 mg from January 2017 through June 2025. Patients who received an investigative CAR-T product were excluded. Results Fourteen patients were included in the final analysis. Median age was 71. Six patients were female. Twelve patients were treated for DLBCL, 11 with axicabtagene ciloleucel and 1 with lisocabtagene maraleucel. Two patients received brexucabtagene autoleucel, 1 for MCL and 1 for B-ALL.Twelve patients received tocilizumab for cytokine release syndrome (CRS); median doses given was 2. Seven patients received anakinra. Median ICANS grade at time of IT administration was 3 (1-4). Median ICE score at time of IT administration was 2 (0-8). Median number of ICANS days at time of IT was 4 (2-9). All patients had complete resolution of ICANS with an eventual ICE score of 10. Median time from IT administration to ICANS resolution was 2 days (1-24 days). Patients who received IT < 3 days after ICANS onset had median time to ICANS resolution of 1 day (1-24); those who received IT > 3 days after ICANS onset had median time to resolution of 3 days (1-13). Conclusions ICANS is a serious complication of CAR T-cell therapy, with potential long-term neurologic effects and risk of infections exacerbated by high-dose steroid use. Our analysis shows that IT for ICANS is effective, with all patients resolving to an ICE score of 10 at median time of 2 days after IT administration. Those who received IT therapy earlier vs later from ICANS onset had a shorter time to resolution. Larger prospective studies will help to corroborate these findings.